96 results about "Microsome" patented technology

A pharmaceutical combination comprising an effective amount of at least one cholesterol absorption inhibitor and at least one microsomal triglyceride transfer protein inhibitor (MTP).

The invention provides an air purifying ball. Various mineral elements are prepared into spherical particles which have multiple pores with the porosity of more than 65 percent and contain rich active genes by composite processing. Different components of the spherical particles can be used for natural absorption chemical combination, decomposition and diffusion in any space. The air purifying ball is suitable for air purification in any space and purified air in a forced ventilation filter. The invention can also extract effective components-air active microsomes which can purify air and improve air quality from about 60 plants by using the spherical particles as carriers and using processes, such as distillation, backflow, press squeezing, supercritical fluid extraction, and the like, select and form the combination of the air active microsomes according to different odor classes of an odor source to form active liquid-an air solvent by composite processing so as to carry or infiltrate the spherical particles so that the air purifying ball is formed.

Combination therapies for treating obesity or related eating disorders and / or reducing food consumption are described herein which comprises administering a therapeutically effective amount of a cannabinoid-1 (CB-1) receptor antagonist and an intestinal-acting microsomal triglyceride transfer protein inhibitor (MTPi) to an animal in need of such treatment. The CB-1 receptor antagonist and intestinal-acting MTPi may be administered separately or together.

The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitade) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe). Co-administration of the MTP inhibitor with the CAI produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and / or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit.

The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a HMG-CoA reductase inhibitor (for example simvastatin or atorvastatin). Co-administration of the MTP inhibitor with the HMG-CoA reductase inhibitor produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and / or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit.

The preparation and use of nucleic acid fragments encoding fatty acid desaturase enzymes are described. The invention permits alteration of plant lipid composition. Chimeric genes incorporating such nucleic acid fragments with suitable regulatory sequences may be used to create transgenic plants with altered levels of unsaturated fatty acids.

The invention relates to a method and equipment for detecting tumor microsomes, and especially relates to and discloses a method and a detector for detecting tumor microsomes by using laser tweezers and micro fluidics. The detection method comprises the steps that: laser tweezers of different polarizations are generated; dual-beam double laser tweezers are used for focusing, and particles combined with tumor microsome antibodies in a channel of a micro fluidic chip are captured by the tweezers; a sample to be detected is mixed with the particles combined with tumour microsome antibodies; changes of physical parameters of the particles combined with tumor microsome antibodies before and after being mixed with the sample are collected by the detector, and qualification and accurate quantitation of the sample requiring detection can be carried out according to the parameters. The detector comprises a laser system, a nanometer positioning system, a camera system, optical parts, mechanical parts, a data collecting and transmitting system, and automatic controlling and image processing application software. According to the invention, single tumor microsome particle can be detected, and the method and the equipment are characterized in high specificity, simple operation, short detection period, high sensitivity, and good repeatability. Also, with the method and the equipment, blood samples can be re-detected.

The invention relates to cytochrome P450, specifically to a method for measuring the content of a biomarker-cytochrome P450 in earthworm viscera, which comprises the following steps of: (1) soaking a live earthworm in glycerol solution, and immediately dissecting and taking out the viscera thereof; (2) cleaning the viscera with cold saline water, transferring to a homogenization buffer, breaking cells with a glass tissue grinder, centrifuging with a ultra-speed centrifuge at low temperature (3DEG C) and 10,000g for 20min, centrifuging the supernatant at 150,000g for 90min, removing the supernatant, and collecting microsome sediment; and (3) dissolving the microsome sediment in a storage buffer, mixing, and measuring the total amount of cytochrome P450 and the protein content in the microsome suspension. The total amount of cytochrome P450 is quantified with sodium hydrosulfite-reduced CO difference spectra method. The invention has the advantages of simplicity, rapidness, low consumption, and accurate qualification and quantitation.

Isolated metabolites of the cyclosporine analog ISA247 are disclosed, including in vitro methods for their preparation. The metabolites comprise a chemical modification of ISA247, wherein the modification is at least one reaction selected from the group consisting of hydroxylation, N-demethylation, diol formation, epoxide formation, and intramolecular cyclization phosphorylation, sulfation, glucuronide formation and glycosylation. Methods of preparation include semi-synthetic methods, wherein metabolites of ISA247 are produced from the microsomal extracts of animal liver cells, or from cultures using microorganisms, and completely synthetic methods, such as chemically modifying the parent compound or isolated metabolites using organic synthetic methods.

The present invention provides cell free preparations of protozoan microsomes, wherein the cell free preparation of protozoan microsomes demonstrate the ability to translocate a protozoan polypeptide into the microsome, methods of preparing cell free preparations of protozoan microsomes, and methods of using cell free preparations of protozoan microsomes.

The invention discloses an anti-LKM (liver-kidney microsomal) 1 antibody detection kit and a detection method. The kit comprises biotinylation LKM-1 antigen, a calibrator, a quality control material, an AP (alkaline phosphatase)-anti-human IgG (intravenous gamma globulin) antibody, a magnetic particle reagent, a chemiluminescent substrate and a cleaning liquid. According to the detection method, the reagent in the kit is used for detection of the sample. With the adoption of the scheme, a full-automatic magnetism particulate chemiluminescent detection method is adopted for selection of an alkaline phosphatase AP-adamantane AMPPD system, and the kit has the advantages of good stability, high sensitivity, good repeatability and the like; meanwhile, the detection time is greatly shortened, the total time required for one test is about 50 minutes, the operation is simple and convenient, and full-automatic detection is really realized.

The invention discloses a subcellular structure characteristic N-linked carbohydrate chain and the application thereof and belongs to the technical field of glycobiology. Bladder YTS1 cells are used as the experiment material, the protein components of four subcellular structures (microsome, chondriosome, cell nucleus and cytoplasm) are obtained with the differential centrifugation method, and subcellular structure difference carbohydrate chain distribution is displayed through the change of the type and structure of subcellular structure protein galactosylated modification identified through a united lectin chip and a mass spectrum (PS) respectively. Subcellular structure characteristic N-linked glycan of ten kinds of human bladder YTS1 cells is obtained. By means of characteristic N-linked glycan, indirect detection and qualitative or quantitative detection of other target substances in corresponding subcellular structures can be achieved.

This invention relates to compounds of formula Itheir use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and / or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, Ra, Rb have meanings given in the description.

The invention relates to a multilayer microsome and an anti-glare film formed by applying the multilayer microsome. The anti-glare film contains transparent resin and a plurality of multilayer microsomes, wherein the multilayer microsomes are evenly distributed in the transparent resin. Since the multilayer microsomes consist of at least two layers of different transparent substances, the phenomenon of different light refractive indexes can be generated, and light scattering and refraction are caused further.